<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03180970</url>
  </required_header>
  <id_info>
    <org_study_id>2017SDU-QILU-G002</org_study_id>
    <nct_id>NCT03180970</nct_id>
  </id_info>
  <brief_title>Different Lugol's Solution Concentration for Image Quality of Esophageal Lesions in Chromoendoscopy With Iodine Staining</brief_title>
  <official_title>Different Lugol's Solution Concentration for Image Quality of Early Esophageal Squamous Neoplasia in Chromoendoscopy With Iodine Staining</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether lower Lugol's solution concentration can
      perceive the same image quality of early esophageal squamous neoplasia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chromoendoscopy using Lugol's solution is effective for the detection of early esophageal
      squamous neoplasia. However, this modality may cause severe chest pain and discomfort owing
      to mucosal irritation.

      This study was to test whether a lower concentration of Lugol's solution can provide
      satisfied image quality of early esophageal squamous neoplasia and has lower mucosal
      irritation.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2017</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Image Quality of Esophageal Lesions</measure>
    <time_frame>seven months</time_frame>
    <description>Evaluated by Image J software (National Institutes of Health)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Questionnaire of endoscopists' subjective assessments</measure>
    <time_frame>intraoperative</time_frame>
    <description>The picture will be rated for quality according to color contrast of esophageal lesions after iodine sprayed by the endoscopist performing the examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete resection/R0 resection rate</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mucosal change of the stomach in white-light endoscopy after Lugol's solution sprayed.</measure>
    <time_frame>intraoperative</time_frame>
    <description>The endoscopic findings of the greater curvature of the gastric body where the agent collected will be evaluated based on the following findings:fold thickening, exudates, ulcers, and hemorrhage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The amount of Lugol's solution</measure>
    <time_frame>intraoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe adverse events (allergic reactions, esophageal burns, spasms and even perforation)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Image Quality of Early Esophageal Squamous Neoplasia</condition>
  <condition>Endoscopists'Subjective Assessments</condition>
  <arm_group>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group patients were given dosages of 1.2% Lugol's solution for chromoendoscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group patients were given dosages of 1.0% Lugol's solution for chromoendoscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group patients were given dosages of 0.8% Lugol's solution for chromoendoscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group patients were given dosages of 0.6% Lugol's solution for chromoendoscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group patients were given dosages of 0.4% Lugol's solution for chromoendoscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1.2% Lugol's solution</intervention_name>
    <description>1.2% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).</description>
    <arm_group_label>group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1.0% Lugol's solution</intervention_name>
    <description>1.0% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).</description>
    <arm_group_label>group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.8% Lugol's solution</intervention_name>
    <description>0.8% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).</description>
    <arm_group_label>group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.6% Lugol's solution</intervention_name>
    <description>0.6% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).</description>
    <arm_group_label>group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.4% Lugol's solution</intervention_name>
    <description>0.4% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).</description>
    <arm_group_label>group 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with early esophageal squamous neoplasia who underwent endoscopic submucosal
        dissection.

        Exclusion Criteria:

        After esophageal surgery or endoscopic treatment ; Known esophageal radiotherapy or
        chemotherapy ; Esophageal stenosis; Acute bleeding; A known allergy to iodine; Coagulopathy
        (prothrombin time &lt;50% of control, partial thromboplastin time &gt;50 seconds); Having food
        retention; Severe hepatic ,renal, cardiovascular or metabolic dysfunction ; Being pregnant
        or lactating.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiuli Zuo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qilu Hospital of Shandong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiuli Zuo, PhD</last_name>
    <phone>15588818685</phone>
    <phone_ext>053188369277</phone_ext>
    <email>zuoxiuli@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Qilu Hospital, Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiuli Zuo, PhD</last_name>
      <phone>15588818685</phone>
      <phone_ext>053188369277</phone_ext>
      <email>zuoxiuli@sina.com</email>
    </contact>
    <investigator>
      <last_name>Junyan Qu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2017</study_first_submitted>
  <study_first_submitted_qc>June 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2017</study_first_posted>
  <last_update_submitted>June 7, 2017</last_update_submitted>
  <last_update_submitted_qc>June 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Xiuli Zuo</investigator_full_name>
    <investigator_title>director of Qilu Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Lugol's solution</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

